PURE Bioscience, Inc. (PURE)

PURE Bioscience Income Statement

Financials in millions USD. Fiscal year is August - July.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 31, 2025	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022	Jul 31, 2021
Revenue	2.2	1.96	1.88	1.85	3.93
Revenue Growth (YoY)	12.17%	4.58%	1.29%	-52.81%	-43.23%
Cost of Revenue	0.9	0.81	0.91	0.85	1.85
Gross Profit	1.3	1.15	0.97	1	2.08
Selling, General & Admin	3.26	3.98	4.3	4.05	4.05
Research & Development	0.32	0.3	0.3	0.32	0.34
Operating Expenses	3.58	4.28	4.6	4.37	4.39
Operating Income	-2.27	-3.13	-3.63	-3.37	-2.31
Interest Expense	-0.3	-0.16	-0.01	-0.01	-0
Other Non Operating Income (Expenses)	0.17	-0	-0	-	-0
EBT Excluding Unusual Items	-2.4	-3.29	-3.65	-3.38	-2.32
Asset Writedown	-	-0.06	-0.32	-0.35	-
Other Unusual Items	-	-	-	0.24	-
Pretax Income	-2.4	-3.35	-3.96	-3.49	-2.32
Net Income	-2.4	-3.35	-3.96	-3.49	-2.32
Net Income to Common	-2.4	-3.35	-3.96	-3.49	-2.32
Shares Outstanding (Basic)	112	112	111	89	87
Shares Outstanding (Diluted)	112	112	111	89	87
Shares Change (YoY)	0.01%	0.41%	25.41%	1.91%	3.03%
EPS (Basic)	-0.02	-0.03	-0.04	-0.04	-0.03
EPS (Diluted)	-0.02	-0.03	-0.04	-0.04	-0.03
Free Cash Flow	-2.02	-2.53	-3.31	-2.5	-1.69
Free Cash Flow Per Share	-0.02	-0.02	-0.03	-0.03	-0.02
Gross Margin	59.17%	58.69%	51.73%	53.97%	52.84%
Operating Margin	-103.18%	-159.50%	-193.29%	-181.87%	-58.85%
Profit Margin	-108.95%	-170.66%	-211.03%	-188.40%	-59.05%
Free Cash Flow Margin	-91.51%	-128.94%	-176.40%	-134.86%	-42.98%
EBITDA	-2.27	-2.98	-3.51	-3.16	-2.14
EBITDA Margin	-103.09%	-151.96%	-187.05%	-170.37%	-54.47%
D&A For EBITDA	0	0.15	0.12	0.21	0.17
EBIT	-2.27	-3.13	-3.63	-3.37	-2.31
EBIT Margin	-103.18%	-159.50%	-193.29%	-181.87%	-58.85%
Revenue as Reported	2.2	1.96	1.88	1.85	3.93

Updated Jul 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.